On Tuesday, Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP), lost -1.55% to $13.32.
Aquinox Pharmaceuticals, (AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, declared that it will host an R&D Day in New York City on Wednesday, October 7thfrom 8:30 AM to 10:00 AM Eastern Time. This event will provide an opportunity to hear from a distinguished clinical expert on bladder pain syndrome/interstitial cystitis (BPS/IC), a debilitating disease affecting millions in the U.S. Aquinox will also be reviewing the full data from its recently accomplished LEADERSHIP trial and provide an update on the clinical development plans for AQX-1125 in BPS/IC.
Senior members of Aquinox’s executive team will be in attendance, counting David Main, President & CEO and Dr. Stephen Shrewsbury, Senior VP of Clinical Development and Chief Medical Officer. Also attending will be Dr. Robert Evans M.D., Associate Professor of Urology at Wake Forest Baptist Health University and Clinical Instructor, Wake Forest School of Medicine Department of Urology. Dr. Evans has been a practicing urologist for more than 25 years while serving on the American Urologic Association guidelines committee for interstitial cystitis in addition to the Medical Advisory Board and the Board of Trustees of the Interstitial Cystitis Association. Dr. Evans is recognized as a foremost authority in the understanding, diagnosis and treatment of BPS/IC.
Aquinox Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics for diseases in the areas of inflammation and immuno-oncology.
Shares of United Microelectronics Corp (ADR) (NYSE:UMC), declined -1.14 % to $1.73, during its last trading session.
United Microelectronics Corporation, declared that it has entered high volume production for touch IC applications manufactured on UMC’s 0.11um eFlash process. The specialized technology, first introduced by UMC in late 2012 as the foundry industry’s first, true 12-volt aluminum back-end-of-line (BEoL) process, is developed for next generation touch controller IC and IoT applications. Contrast to 0.18um, 0.11um provides smaller and faster logic devices for higher performance, while enabling the integration of higher density embedded Flash and SRAM for use in microcontrollers for touch-screen products of all sizes.
Kurt Huang, senior director of corporate marketing at UMC, said, “Touch panels have become the predominant interface used for recently’s electronics. A key advantage of UMC’s touch platform solution is that we provide the 0.11um eFlash with proprietary flash macro design services to IC designers. We also offer the best cost vs. performance by incorporating an aluminum BEoL process to serve the highly competitive touch IC market. In addition, just like our 0.18um eFlash, support for true 12-volt power meets the high signal-to-noise ratio (SNR) requirements needed for recently’s larger touch screens and “hovering” applications used during web navigation on touch surfaces.”
United Microelectronics Corporation provides semiconductor wafer foundry solutions. Its foundry solutions comprise silicon verification, libraries and IP, design verification, design for manufacturing, MM/RF foundry design kit and design support manual, and design flow reference, in addition to mask services, such as mask inspection, IP protection and data preparation, and tape-out status tracking.
At the end of Tuesday’s trade, Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), lost -2.70% to $6.86.
SciClone Pharmaceuticals, declared that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 2015 Aegis Capital Growth Conference at 11:25 am PT on Friday, October 9, 2015, at The Encore at Wynn Las Vegas.
SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments, counting China and the rest of the world (the United States and Hong Kong). The Company’s lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers.
Finally, Extended Stay America Inc (NYSE:STAY), ended its last trade with 1.03% gain, and closed at $17.71.
Extended Stay America, declared that the Company will release its third quarter results on Tuesday, October 27, 2015, before the opening of trading on the New York Stock Exchange. A conference call will be held on Tuesday, October 27, 2015 at 9:30 a.m. Eastern Time.
Extended Stay America, Inc. (Extended Stay) is an integrated owner/operator of company-branded hotels in North America. The Company’s business operates in the extended stay lodging industry. The Company owns and operates about 682 hotels comprising about 76,000 rooms located in 44 states across the United States and in Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
